However, in chronic hepatitis C patients with HBV co-infection, reactivation of HBV during DAA treatment has been reported, with incidence ranging from 19–30% in patients with HBsAg seropositivity and 0.8–2.4% in resolved or occult HBV [8,9,10,11,12]; about 9% of patients developed clinical hepatitis with overt elevation of ALT level [8], which causes liver inflammation and deteriorating liver fibrosis. The gene discussed is GPT; the disease is coinfection.